EA200970359A1 - Статин и омега-3 жирные кислоты для снижения уровней аро-в - Google Patents

Статин и омега-3 жирные кислоты для снижения уровней аро-в

Info

Publication number
EA200970359A1
EA200970359A1 EA200970359A EA200970359A EA200970359A1 EA 200970359 A1 EA200970359 A1 EA 200970359A1 EA 200970359 A EA200970359 A EA 200970359A EA 200970359 A EA200970359 A EA 200970359A EA 200970359 A1 EA200970359 A1 EA 200970359A1
Authority
EA
Eurasian Patent Office
Prior art keywords
reduce
omega
levels
fatty acids
aro
Prior art date
Application number
EA200970359A
Other languages
English (en)
Other versions
EA018734B1 (ru
Inventor
Рулоф М. Л. Ронген
Роберт А. Шалвиц
Дуглас Клинг
Ральф Т. мл. Дойл
Original Assignee
Релайэнт Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/742,292 external-priority patent/US20070191467A1/en
Application filed by Релайэнт Фармасьютикалз, Инк. filed Critical Релайэнт Фармасьютикалз, Инк.
Publication of EA200970359A1 publication Critical patent/EA200970359A1/ru
Publication of EA018734B1 publication Critical patent/EA018734B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Способ применения комбинированного введения или стандартной дозировки комбинации ингибитора HMG-CoA и омега-3 жирных кислот для снижения уровней аполипопротеина-В. Данные способы, в частности, можно применять при лечении пациентов с гипертриглицеридемией или гиперхолестеринемией, или смешанной дислипидемией, коронарной болезнью сердца (CHD), сосудистым заболеванием, атеросклеротическим заболеванием и связанными с ними состояниями, и для предупреждения или уменьшения сердечно-сосудистых, сердечных и сосудистых явлений.
EA200970359A 2006-10-10 2007-09-07 СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B EA018734B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85028006P 2006-10-10 2006-10-10
US11/742,292 US20070191467A1 (en) 2004-12-06 2007-04-30 Statin and omega-3 fatty acids for lipid therapy
PCT/US2007/019539 WO2008045170A2 (en) 2006-10-10 2007-09-07 Statin and omega-3 fatty acids for reduction of apo-b levels

Publications (2)

Publication Number Publication Date
EA200970359A1 true EA200970359A1 (ru) 2009-10-30
EA018734B1 EA018734B1 (ru) 2013-10-30

Family

ID=39283166

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200970359A EA018734B1 (ru) 2006-10-10 2007-09-07 СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B
EA200970360A EA200970360A1 (ru) 2006-10-10 2007-10-10 Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-в

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200970360A EA200970360A1 (ru) 2006-10-10 2007-10-10 Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-в

Country Status (10)

Country Link
EP (1) EP2089014A4 (ru)
JP (1) JP2010505956A (ru)
KR (1) KR20090080070A (ru)
CN (2) CN101553221A (ru)
AU (1) AU2007307007A1 (ru)
BR (1) BRPI0719182A2 (ru)
CA (1) CA2672919A1 (ru)
EA (2) EA018734B1 (ru)
MX (1) MX2009003921A (ru)
WO (1) WO2008045465A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
EP2083622A4 (en) * 2006-10-18 2009-12-09 Reliant Pharmaceuticals Inc METHODS OF USING OMEGA-3 FATTY ACIDS TO REDUCE LP-PLA2 RATES
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
DK2596786T3 (da) 2009-02-10 2020-02-24 Amarin Pharmaceuticals Ie Ltd Anvendelse af eicosapentaensyreethylester til behandling af hypertriglyceridæmi
MX2011011538A (es) 2009-04-29 2012-06-13 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PL3318255T3 (pl) 2009-06-15 2021-09-06 Amarin Pharmaceuticals Ireland Limited Kompozycje i sposoby leczenia udaru u pacjenta z jednoczesną terapią statyną
RU2758369C2 (ru) 2009-09-23 2021-10-28 Амарин Фармасьютикалз Айрлэнд Лимитед Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ757815A (en) 2010-11-29 2020-05-29 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
IL313596A (en) 2012-06-29 2024-08-01 Amarin Pharmaceuticals Ie Ltd Eicosapentaenoic acid and docosapentaenoic acid for use as a drug to reduce the risk of cardiovascular-related death
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
WO2014034871A1 (ja) * 2012-08-30 2014-03-06 株式会社 三和化学研究所 脂質異常症の予防又は治療薬
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
AU2014381733B2 (en) * 2014-02-05 2020-09-03 Newamsterdam Pharma B.V. Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2020068163A1 (en) 2018-09-24 2020-04-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014359A1 (en) * 2001-03-16 2004-02-19 Thomas Jefferson University Regulation of apob in treatment and drug screening for cardiovascular and metabolic disorders or syndromes
AU2005314361B2 (en) * 2004-12-06 2012-04-12 Glaxosmithkline Llc Omega-3 fatty acids and dyslipidemic agent for lipid therapy
JP2009515815A (ja) * 2005-07-18 2009-04-16 レリアント ファーマスーティカルズ インコーポレイテッド アゼチジノン系コレステロール吸収阻害剤及びオメガ−３脂肪酸を用いた治療、並びにそれらの併用品

Also Published As

Publication number Publication date
EA018734B1 (ru) 2013-10-30
EP2089014A1 (en) 2009-08-19
WO2008045465A1 (en) 2008-04-17
MX2009003921A (es) 2009-08-31
EP2089014A4 (en) 2009-12-09
KR20090080070A (ko) 2009-07-23
CN101553221A (zh) 2009-10-07
EA200970360A1 (ru) 2009-10-30
JP2010505956A (ja) 2010-02-25
CA2672919A1 (en) 2008-04-17
CN101553220A (zh) 2009-10-07
BRPI0719182A2 (pt) 2014-10-21
AU2007307007A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
EA200970359A1 (ru) Статин и омега-3 жирные кислоты для снижения уровней аро-в
MX2009003920A (es) Estatina y acidos grasos omega 3 para reducir los niveles de apo b.
EA200701229A1 (ru) Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
NZ711283A (en) Compositions and methods for lowering triglycerides without raising ldl-c levels
CL2021003222A1 (es) (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
EA200800356A1 (ru) Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
BR112014032905A2 (pt) métodos de redução do risco de um evento cardiovascular em um sujeito em terapia com estatina
NZ720946A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
RU2470642C2 (ru) Аналоги птерина для лечения состояния, чувствительного к вн4
ITMI20020269A0 (it) Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
NZ552389A (en) Statin pharmaceutical compositions and related methods of treatment
RU2008108078A (ru) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
CY1110133T1 (el) Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ
WO2008088415A8 (en) Omega-3 fatty acids for reduction of lp-pla2 levels
EA200870019A1 (ru) Лактамовые соединения и способы их применения
WO2006086108A3 (en) Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors
NO20065152L (no) Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
BRPI0709157A8 (pt) derivados de buprenorfina e usos dos mesmos
JP2019533715A5 (ru)
NZ603207A (en) Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
RU2014145102A (ru) Комбинация
EA200971020A1 (ru) Лечение сердечно-сосудистого заболевания и дислипидемии с использованием ингибиторов секреторной фосфолипазы а(spla) и способы комбинированного лечения с ингибитором spla

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU